Lixte Biotechnology Competitors

Lixte Biotechnology (NASDAQ:LIXT) and Neptune Wellness Solutions (NASDAQ:NEPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Volatility and Risk

Lixte Biotechnology has a beta of -1.15, meaning that its share price is 215% less volatile than the S&P 500. Comparatively, Neptune Wellness Solutions has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500.

Profitability

This table compares Lixte Biotechnology and Neptune Wellness Solutions' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Lixte Biotechnology and Neptune Wellness Solutions' gross revenue, earnings per share and valuation.

Lixte Biotechnology has higher earnings, but lower revenue than Neptune Wellness Solutions.

Institutional & Insider Ownership

17.2% of Neptune Wellness Solutions shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lixte Biotechnology and Neptune Wellness Solutions, as reported by MarketBeat.

Neptune Wellness Solutions has a consensus target price of $6.00, indicating a potential upside of 263.64%. Given Neptune Wellness Solutions' higher probable upside, analysts clearly believe Neptune Wellness Solutions is more favorable than Lixte Biotechnology.

Summary

Neptune Wellness Solutions beats Lixte Biotechnology on 5 of the 8 factors compared between the two stocks.

Lixte Biotechnology (NASDAQ:LIXT) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Volatility and Risk

Lixte Biotechnology has a beta of -1.15, meaning that its share price is 215% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.

Profitability

This table compares Lixte Biotechnology and Iterum Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Lixte Biotechnology and Iterum Therapeutics' gross revenue, earnings per share and valuation.

Lixte Biotechnology has higher earnings, but lower revenue than Iterum Therapeutics.

Institutional & Insider Ownership

10.1% of Iterum Therapeutics shares are owned by institutional investors. 22.1% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lixte Biotechnology and Iterum Therapeutics, as reported by MarketBeat.

Iterum Therapeutics has a consensus target price of $4.8750, indicating a potential upside of 185.09%. Given Iterum Therapeutics' higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than Lixte Biotechnology.

Summary

Iterum Therapeutics beats Lixte Biotechnology on 6 of the 7 factors compared between the two stocks.

Lixte Biotechnology (NASDAQ:LIXT) and Strongbridge Biopharma (NASDAQ:SBBP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Volatility and Risk

Lixte Biotechnology has a beta of -1.15, meaning that its share price is 215% less volatile than the S&P 500. Comparatively, Strongbridge Biopharma has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.

Profitability

This table compares Lixte Biotechnology and Strongbridge Biopharma's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Lixte Biotechnology and Strongbridge Biopharma's gross revenue, earnings per share and valuation.

Lixte Biotechnology has higher earnings, but lower revenue than Strongbridge Biopharma.

Institutional & Insider Ownership

58.3% of Strongbridge Biopharma shares are owned by institutional investors. 6.6% of Strongbridge Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lixte Biotechnology and Strongbridge Biopharma, as reported by MarketBeat.

Strongbridge Biopharma has a consensus target price of $7.1250, indicating a potential upside of 129.84%. Given Strongbridge Biopharma's higher probable upside, analysts clearly believe Strongbridge Biopharma is more favorable than Lixte Biotechnology.

Summary

Strongbridge Biopharma beats Lixte Biotechnology on 6 of the 9 factors compared between the two stocks.

Lixte Biotechnology (NASDAQ:LIXT) and Concert Pharmaceuticals (NASDAQ:CNCE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Institutional & Insider Ownership

69.7% of Concert Pharmaceuticals shares are owned by institutional investors. 10.1% of Concert Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Lixte Biotechnology has a beta of -1.15, meaning that its share price is 215% less volatile than the S&P 500. Comparatively, Concert Pharmaceuticals has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Valuation and Earnings

This table compares Lixte Biotechnology and Concert Pharmaceuticals' gross revenue, earnings per share and valuation.

Lixte Biotechnology has higher earnings, but lower revenue than Concert Pharmaceuticals.

Profitability

This table compares Lixte Biotechnology and Concert Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lixte Biotechnology and Concert Pharmaceuticals, as reported by MarketBeat.

Concert Pharmaceuticals has a consensus target price of $21.00, indicating a potential upside of 208.82%. Given Concert Pharmaceuticals' higher probable upside, analysts clearly believe Concert Pharmaceuticals is more favorable than Lixte Biotechnology.

Summary

Concert Pharmaceuticals beats Lixte Biotechnology on 6 of the 9 factors compared between the two stocks.

OptiNose (NASDAQ:OPTN) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Volatility & Risk

OptiNose has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -1.15, indicating that its share price is 215% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for OptiNose and Lixte Biotechnology, as provided by MarketBeat.com.

OptiNose currently has a consensus price target of $19.00, indicating a potential upside of 381.01%. Given OptiNose's higher possible upside, research analysts plainly believe OptiNose is more favorable than Lixte Biotechnology.

Earnings and Valuation

This table compares OptiNose and Lixte Biotechnology's revenue, earnings per share (EPS) and valuation.

Lixte Biotechnology has lower revenue, but higher earnings than OptiNose.

Insider and Institutional Ownership

62.9% of OptiNose shares are owned by institutional investors. 38.0% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OptiNose and Lixte Biotechnology's net margins, return on equity and return on assets.

Summary

OptiNose beats Lixte Biotechnology on 6 of the 9 factors compared between the two stocks.

Lixte Biotechnology (NASDAQ:LIXT) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Risk & Volatility

Lixte Biotechnology has a beta of -1.15, suggesting that its stock price is 215% less volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Lixte Biotechnology and Tiziana Life Sciences, as provided by MarketBeat.

Tiziana Life Sciences has a consensus price target of $9.50, indicating a potential upside of 186.14%. Given Tiziana Life Sciences' higher possible upside, analysts clearly believe Tiziana Life Sciences is more favorable than Lixte Biotechnology.

Valuation and Earnings

This table compares Lixte Biotechnology and Tiziana Life Sciences' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Lixte Biotechnology and Tiziana Life Sciences' net margins, return on equity and return on assets.

Summary

Tiziana Life Sciences beats Lixte Biotechnology on 3 of the 3 factors compared between the two stocks.